Bank of New York Mellon’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-122,693
| Closed | -$392K | – | 4663 |
|
|
2022
Q2 | $392K | Sell |
122,693
-4,391
| -3% | -$17.1K | ﹤0.01% | 3738 |
|
|
2022
Q1 | $543K | Buy |
127,084
+5,781
| +5% | +$25.2K | ﹤0.01% | 3662 |
|
|
2021
Q4 | $564K | Buy |
121,303
+51,809
| +75% | +$216K | ﹤0.01% | 3732 |
|
|
2021
Q3 | $278K | Sell |
69,494
-1,789
| -3% | -$7.1K | ﹤0.01% | 4071 |
|
|
2021
Q2 | $306K | Sell |
71,283
-49,065
| -41% | -$210K | ﹤0.01% | 3962 |
|
|
2021
Q1 | $509K | Buy |
120,348
+54,925
| +84% | +$303K | ﹤0.01% | 3678 |
|
|
2020
Q4 | $254K | Sell |
65,423
-2,598
| -4% | -$11.1K | ﹤0.01% | 3892 |
|
|
2020
Q3 | $274K | Sell |
68,021
-4,706
| -6% | -$19.5K | ﹤0.01% | 3753 |
|
|
2020
Q2 | $309K | Buy |
72,727
+182
| +0.3% | +$1.11K | ﹤0.01% | 3684 |
|
|
2020
Q1 | $304K | Buy |
72,545
+1,136
| +2% | +$7.17K | ﹤0.01% | 3591 |
|
|
2019
Q4 | $281K | Sell |
71,409
-9,752
| -12% | -$57.6K | ﹤0.01% | 3829 |
|
|
2019
Q3 | $715K | Buy |
81,161
+3,169
| +4% | +$29.9K | ﹤0.01% | 3353 |
|
|
2019
Q2 | $721K | Sell |
77,992
-13,293
| -15% | -$100K | ﹤0.01% | 3415 |
|
|
2019
Q1 | $587K | Buy |
91,285
+6,135
| +7% | +$40K | ﹤0.01% | 3474 |
|
|
2018
Q4 | $803K | Sell |
85,150
-5,799
| -6% | -$87.3K | ﹤0.01% | 3229 |
|
|
2018
Q3 | $1.83M | Sell |
90,949
-1,277
| -1% | -$33.4K | ﹤0.01% | 2890 |
|
|
2018
Q2 | $2.69M | Buy |
92,226
+5,964
| +7% | +$184K | ﹤0.01% | 2686 |
|
|
2018
Q1 | $2.57M | Buy |
86,262
+2,508
| +3% | +$80.9K | ﹤0.01% | 2680 |
|
|
2017
Q4 | $2.69M | Buy |
83,754
+10
| +0% | +$327 | ﹤0.01% | 2673 |
|
|
2017
Q3 | $2.91M | Buy |
83,744
+897
| +1% | +$28.8K | ﹤0.01% | 2606 |
|
|
2017
Q2 | $2.47M | Buy |
82,847
+6,667
| +9% | +$191K | ﹤0.01% | 2723 |
|
|
2017
Q1 | $2.27M | Buy |
76,180
+4,619
| +6% | +$118K | ﹤0.01% | 2779 |
|
|
2016
Q4 | $1.25M | Buy |
71,561
+3,233
| +5% | +$62K | ﹤0.01% | 3128 |
|
|
2016
Q3 | $1.63M | Buy |
68,328
+959
| +1% | +$18.1K | ﹤0.01% | 2893 |
|
|
2016
Q2 | $1.08M | Sell |
67,369
-4,767
| -7% | -$85.5K | ﹤0.01% | 3086 |
|
|
2016
Q1 | $1.51M | Buy |
72,136
+14,724
| +26% | +$263K | ﹤0.01% | 2827 |
|
|
2015
Q4 | $1.55M | Sell |
57,412
-6,744
| -11% | -$184K | ﹤0.01% | 2873 |
|
|
2015
Q3 | $1.78M | Buy |
64,156
+19,615
| +44% | +$618K | ﹤0.01% | 2806 |
|
|
2015
Q2 | $1.09M | Buy |
+44,541
| New | +$918K | ﹤0.01% | 3291 |
|
Bank of New York Mellon's LJPC Position: Q3 2022 in Review
Bank of New York Mellon sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 122,693 shares — an estimated $392K sold.
Bank of New York Mellon first reported a position in LJPC in Q2 2015 and held it in 29 quarters. The position peaked at $2.91M in Q3 2017. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- Bank of New York Mellon reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- Bank of New York Mellon sold 122,693 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $392K.
- Bank of New York Mellon first reported a position in La Jolla Pharmaceutical Company in Q2 2015 and held it in 29 quarters.
- Bank of New York Mellon's La Jolla Pharmaceutical Company position peaked at $2.91M in Q3 2017.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on Bank of New York Mellon's 13F filing for Q3 2022, filed 14 Nov 2022.